View More
From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care
Jesús G. Berdeja, MD
Caron A. Jacobson, MD
Released: June 30, 2022
Experts describe key takeaways from a live symposium on HER2-, HER3-, and TROP2-targeted therapies and treatment approaches for patients, from Clinical Care Options (CCO)
Aditya Bardia, MD, MPH
Yelena Y. Janjigian, MD
Sandip P. Patel, MD
Released: June 8, 2022
Patient-reported outcomes from the HIMALAYA study of durvalumab with or without tremelimumab vs sorafenib in unresectable hepatocellular carcinoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers
Michael J. Pishvaian, MD, PhD
Released: June 3, 2022
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.